GRAND ROUNDS AND PATIENT VIEWING
Zoom
Resident Expert Talks

Photodynamic therapy: shining a light on efficacy and recent advancements in PDT
Cory Kosche, MD, Chief, PGY-4 Resident, Department of Dermatology, UCSF
Objectives:
1. Understand the fundamental principles of photodynamic therapy, including the mechanisms of photosensitization and light activation
2. Identify and differentiate between various sensitizing medications and light sources utilized in photodynamic therapy
3. Review expanded indications for photodynamic therapy beyond traditional dermatological applications including neoplastic,
inflammatory, and cosmetic conditions

Surgical Perspectives on Hidradenitis Suppurativa: Evaluating Procedural Indications, Techniques, and Outcomes
Fiatsogbe Dzuali, MD, PGY-4 Resident, Department of Dermatology, UCSF
Objectives:
1. Understanding the Indications for Surgical Intervention in Hidradenitis Suppurativa: Gain insight into the clinical criteria and patient
factors that necessitate surgical management, including the stages and lesions of HS that benefit most from surgical intervention, and
the decision-making approach to referrals for procedural management.
2. Exploring Procedural Techniques and Their Outcomes in Hidradenitis Suppurativa: Become familiar with various procedural
management options for HS. Discuss the success rates, patient experiences, and potential complications associated with these
methods to better inform patient referrals and manage expectations.

Speaker Disclosures: Cory Kosche, MD and Fiatsogbe Dzuali, MD have stated that they have no financial relationships to disclose.

Moderator Disclosures:Wilson Liao, MD has disclosed that he receives Research Grants from Janssen, Leo PHarma, Regeneron and Amgen and is an Advisor or Reviewer for Solay Health.

Planner Disclosures:
Ilona Frieden, MD has disclosed that she is a consultant for Venthera Bridgebio, Data Safety Monitoring Advisory Board for Pfizer, and Data Reviewer on the NCT02913612 Pediatric Trials
Network-NIH Efficacy, Safety and Pharmacokinetics of Topical Timolol in Infants With Infantile Hemangioma (IH) (TIM01).
Kelly Cordoro, MD, Hunter Shain, PhD and Amanda Twigg, MD have stated they have no relationships to disclose.